CD19 CAR T‐Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70841 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Ofrat Beyar-Katz und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antigens, CD19, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, FDA HHS.
Abstract (Originalsprache)
Richter transformation (RT) is a serious complication of chronic lymphocytic leukaemia (CLL), with poor outcomes. While CAR T‐cells have shown promise in large B‐cell lymphoma, their efficacy in RT remains unclear, and the role of allogeneic stem cell transplant (alloSCT) post‐CAR T‐cells has not been established. This study aimed to assess the clinical response and survival of patients with RT treated with anti‐CD19 CAR T‐cells. This retrospective multicentre study, conducted by the European Research Initiative on CLL (ERIC), included patients with RT who received anti‐CD19 CAR T‐cells between 06/2018 and 01/2024. Progression‐free survival (PFS) and overall survival (OS) were evaluated from CAR T‐cell infusion. Fifty‐four patients with RT were treated with anti‐CD19 CAR T‐cells (academic products, n = 29; commercial products, n = 25). The median age was 63 years, with 72% having an ECOG performance status (PS) of 0 to 1. Seven patients (13%) underwent alloSCT following CAR T‐cell infusion, with the indications being consolidation therapy ( n = 4) and relapse/progression ( n = 3). The overall response rate was 65%, with 46% achieving complete response (CR) at 1 month and 50% at 3 months. The median PFS was 8.0 months (95% CI: 2.1–13.8) and the median OS was 14.4 months (95% CI: 8.8–19.2). The median PFS was 31.6 months for patients achieving CR at 1 or 3 months post CAR T‐cells. Significant factors associated with mortality included high ECOG PS ( p < 0.001), high LDH at CAR T infusion ( p = 0.005), ICANS ( p = 0.046) and no response at 1 month ( p = 0.02). Multivariable Cox regression analysis identified treatment response at 1 month ( p = 0.001) and increasing age ( p = 0.5) as significant predictors of mortality. This study shows encouraging response rates and manageable toxicity for patients with RT treated with both academic and commercially available CAR T‐cell products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
- Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
- Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Ramat Gan, Israel.
- Gray faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Oncoimmunotherapy Unit, Department of Hematology, Hospital Clinic de Barcelona, Barcelona, Spain.
- Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Ofrat Beyar-Katz, Ohad Benjamini, Julio Delgado, Guido Ghilardi, Luca Paruzzo, Tsila Zuckerman, Tamar Tadmor, Giulia Gabrielli, Lydia Scarfo
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- FDA HHS
Zitieren
APA
Beyar-Katz, O., Benjamini, O., Delgado, J., Ruella, M., Ram, R., Grisariu, S., Visentin, A., Vandenberghe, E., Gentile, M., Avigdor, A., Shimoni, A., Shouval, R., Marcus, R., Schuster, S. J., Ortiz-Maldonado, V., Ghilardi, G., Paruzzo, L., Zuckerman, T., Tadmor, T., …, & Herishanu, Y. (2025). CD19 CAR T‐Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70841
Vancouver
Beyar-Katz O, Benjamini O, Delgado J, Ruella M, Ram R, Grisariu S, et al. CD19 CAR T‐Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70841
BibTeX
@article{BeyarKatz2025,
author = {Beyar-Katz, Ofrat and Benjamini, Ohad and Delgado, Julio and Ruella, Marco and Ram, Ron and Grisariu, Sigal and Visentin, Andrea and Vandenberghe, Elisabeth and Gentile, Massimo and Avigdor, Abraham and Shimoni, Avichai and Shouval, Roni and Marcus, Ronit and Schuster, Stephen J and Ortiz-Maldonado, Valentin and Ghilardi, Guido and Paruzzo, Luca and Zuckerman, Tsila and Tadmor, Tamar and Fineman, Riva and Amit, Odelia and Martinez-Cibrian, Nuria and Gabrielli, Giulia and Avni, Batia and Minga, Eva and Shem-Tov, Noga and Scarfo, Lydia and Yerushalmi, Ronit and Nagler, Arnon and Leiba, Ronit and Danylesko, Ivetta and Stamatopoulos, Kostas and Chatzikonstantinou, Thomas and Ghia, Paolo and Herishanu, Yair},
title = {CD19 CAR T‐Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70841}
}
EUVIMED